Positive preliminary data from all five single ascending dose (SAD) cohorts and first three completed multiple ascending dose (MAD) cohorts ...
Palisade Bio (PALI) provided an update on its ongoing Phase 1a/b study of PALI-2108 for the treatment of Ulcerative Colitis, UC. The Company ...
Zacks Investment Research on MSN6d
Palisade Bio (PALI) Upgraded to Buy: What Does It Mean for the Stock?Investors might want to bet on Palisade Bio, Inc. (PALI), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates - ...
Carlsbad, CA, March 04, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage ...
Palisade Bio receives CAD$1.39 million in SR&ED credits for PALI-2108; Phase 1a/b UC study data expected mid-2025. The company is heavily dependent on the success of PALI-2108, which is still in ...
Carlsbad, CA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage ...
CARLSBAD - Palisade Bio, Inc. (NASDAQ: PALI), a clinical-stage biopharmaceutical company, has announced the receipt of 1.39 million Canadian dollars in Scientific Research and Experimental ...
Carlsbad, CA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) ("Palisade”, "Palisade Bio”, or the "Company”), a clinical-stage biopharmaceutical company focused on developing and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback